• English
    • español
    • português (Brasil)
  • English 
    • English
    • español
    • português (Brasil)
  • Login
View Item 
  •   COVID-19
  • Resources in English
  • Technical documents and research evidence on COVID-19
  • View Item
  •   COVID-19
  • Resources in English
  • Technical documents and research evidence on COVID-19
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Summary on Advances in the Development of Vaccines against COVID-19, 3 April 2020

 
Thumbnail
Date
2020-06-03
Author
Pan American Health Organization
Metadata
Show full item record
Abstract
This document presents a brief summary of vaccines in development for COVID-19. At the end of 2019, the new SARS-CoV-2 coronavirus emerged. Although there is not yet a vaccine against this virus, the field of research for its development is advancing rapidly. In February 2020, the World Health Organization (WHO) convened researchers from all over the world to define the research agenda for SARS-CoV-2 drugs and vaccines, through WHO’s Initiative for Research and Development* (R&D Blueprint). The priorities of the R&D Blueprint agenda for vaccine development include the development of the following elements: • Animal models in which to evaluate vaccine effectiveness • Standardized tests to support vaccine development, particularly the evaluation of immune response • Multi-country protocols for phase 2b/3 clinical trials with the intention of facilitating coordination and efficiency • Studies of potency and production processes so that large quantities of vaccines can be produced WHO will also develop a Target Product Profile (TPP), with the intention of defining the expectations and expected characteristics of the vaccine, as well as a web platform to share information. In this context, the Coalition for Epidemic Preparedness Innovations (CEPI) is mobilizing resources for vaccine development to increase the chances of success and to finance clinical trials of some candidate vaccines against SARS-CoV-2. The intention is to have some candidate vaccines that can be submitted to regulatory authorities for approval for general use or for use in outbreak situations...
URI
https://iris.paho.org/handle/10665.2/52273
Collections
  • Technical documents and research evidence on COVID-19

Browse

AllCommunities & CollectionsBy Issue DateAuthorsTitlesCategorySubjectsThis CollectionBy Issue DateAuthorsTitlesCategorySubjects

My Account

LoginRegister

Pan American Health Organization
World Health Organization. Regional Office for the Americas
525 Twenty-third Street, N.W., Washington, D.C. 20037, United States of America

Content Disclaimer (Important notes about the material)

Links

  • WHO International Clinical Trial Registry Platform (ICTRP)
  • WHO Coronavirus disease R&D Blueprint
  • WHO Database of Publications on Coronavirus Disease
  • PAHO Coronavirus Disease
  • PAHO/BIREME Windows of Knowledge COVID-19
  • Evidence aid Coronavirus (COVID-19) resources

  • PAHO Digital Library (IRIS PAHO)
  • Virtual Health Library (VHL)
  • Global Index Medicus (GIM)